Category: CareFusion Corp.
Here's a look at some of the top Wall Street stories for medical device companies this week: Wall Street loves Edwards Lifesciences again; Becton Dickinson to buy CareFusion for $12 billion in cash, stock; Proxy war rages on at Echo Therapeutics; Platinum fires back at Echo Therapeutics over 'rogue' directors; Echo Therapeutics hits back at Platinum Equity
What does news of yet another mega-merger mean for medtech's industry council?
The winds of change in medtech are blowing in the Windy City.
As medtech's best & brightest descended on Chicago for another annual confab at AdvaMed 2014, it was impossible to ignore that the industry has now entered the great age of consolidation with yet another multibillion-dollar healthcare deal.
Becton Dickinson & Co. agrees to pay $12 billion in cash and stock for CareFusion Corp.
ConvaTec is reportedly weighing a sale of the private-equity-owned medical device company next year, even as interest in a Medtronic-like inversion deal mounts from C.R. Bard, CareFusion and 3M.
Here's a look at some of the top Wall Street stories for medical device companies this week: FTC wants more data on Medtronic-Covidien deal, but analysts aren't worried; Greatbatch acquires Uruguay's CCC Medical Devices; T2 Biosystems IPO raises $57M for MRI-based diagnostics; Strong Q4, $750M buyback give CareFusion a boost; Baxano: Strong Q2, new patents can't appease Wall Street
CareFusion gains a couple points after posting a Street-beating 4th quarter and announcing a $750 million share repurchase program.
CareFusion (NYSE:CFN) posted a stellar 4th-quarter, posting double-digit growth in revenues and earnings and beating Wall Street's estimates.
The FDA wants CareFusion to stop selling its anesthesia breathing circuit and the Denver ascites shunt and percutaneous access kit until it applies for clearance for changes made to the devices and clears up some quality control issues at a plant in Illinois.
UPDATED July 24, 2014, with comment from CareFusion.